Paniculitis mediastínica

Lara, Clara Isabel Bayarri; Zafra, J. Ruiz; Massare, Patricia Becerra

doi:10.1157/13112969

Cited by 1 publication

(2 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…6 Extra-abdominal manifestations have only been described as single case reports in the literature. 7,8 Although there is no standardized treatment, corticosteroids are the preferred option among different authors associated with other immunosuppressive or immunomodulatory drugs, such as colchicine, azathioprine, or tamoxifen. 2 On the other hand, there have been reported non-negligible numbers of cases of autoimmune diseases after acute COVID19 disease, proposing SARS-COV2 as a potential trigger for several autoimmune conditions.…”

Section: Discussionmentioning

confidence: 99%

“…In most cases, the disease involves the small‐bowel mesentery and the sigmoid mesentery and less frequently other locations such as peripancreatic region, omentum or retroperitoneum 6 . Extra‐abdominal manifestations have only been described as single case reports in the literature 7,8 . Although there is no standardized treatment, corticosteroids are the preferred option among different authors associated with other immunosuppressive or immunomodulatory drugs, such as colchicine, azathioprine, or tamoxifen 2 …”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Visceral extra‐abdominal panniculitis after COVID19

et al. 2022

View full text Add to dashboard Cite

“Retractile mesenteritis” was the first name given to a rare, benign, inflammatory disease that affects the adipose tissue of the intestinal mesentery and less frequently other locations. Now labeled as mesenteric panniculitis, the pathogenic mechanism remains unclear. Several stimuli could be involved, and it is sometimes associated with other conditions such as malignancy or autoimmune diseases. We present a case of mesenteric panniculitis with extensive abdominal and extra‐abdominal involvement that developed a few months after SARS‐COV2 infection, raising the hypothesis of this virus as a potential trigger for autoinflammatory and autoimmune diseases.

show abstract